therapeutics

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

8 months ago

Akari Therapeutics Releases Virtual Investor What This Means Segment Highlighting its Recently Granted India Patent

June 25, 2025 09:00 ET  | Source: Akari Therapeutics Plc Access the “What This Means” segment here BOSTON and LONDON,…

8 months ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…

8 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…

8 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…

8 months ago

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

9 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:30 ET  | Source: Fulcrum Therapeutics, Inc. CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,…

9 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 05, 2025 18:38 ET  | Source: Xilio Therapeutics, Inc. Total gross proceeds of up to $150.0 million before the…

9 months ago

AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology

Third asset to advance into clinical trials, validating broad potential of Launch-iT platformAll subjects treated with first dose of AVX70371…

9 months ago

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

9 months ago